Bimekizumab-Treated Patients with Active Psoriatic Arthritis Showed Sustained Achievement of Minimal Disease Activity and Remission: Up to 2-Year Results from Two Phase 3 Studies

Author(s):

Author Names in order: Laura C. Coates, Lars Erik Kristensen, Alexis Ogdie, William Tillett, Barbara Ink, Nadine Goldammer, Rajan Bajracharya, Jason Coarse, Ana-Maria Orbai

Presenting Author (at EULAR): Laura C. Coates

Abstract or description:

Abstract/Description Text: We assessed the efficacy of bimekizumab using Minimal Disease Activity (MDA) and Disease Activity Index for Psoriatic Arthritis (DAPSA) up to 2 years in patients with active psoriatic arthritis (PsA) who were bDMARD-naïve or had prior inadequate response/intolerance to TNFi, in the phase 3 trials BE OPTIMAL and BE COMPLETE. Bimekizumab-treated patients with PsA achieved sustained MDA responses and DAPSA improvements from baseline up to 2 years. Improvements were observed across all patient-reported and most clinical components of MDA, with robust improvements observed in joint and skin outcomes. Bimekizumab was well tolerated; no new safety signals were observed.

Abstract Source: EULAR 2024, 12-15 June, Vienna, Austria

These studies were funded by UCB Pharma. All costs associated with development of this presentation were funded by UCB Pharma.